Praxis für Diabetologie, Angiologie und Innere Medizin Eisenach
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Praxis für Diabetologie, Angiologie und Innere Medizin Eisenach researchers are exploring a new drug combination. The study targets cardiovascular disease outcomes. Participants have type 2 diabetes. They also have hypertension.
- Combination of vicadrostat and empagliflozin
- Assessment of cardiovascular death and heart‑failure events
- Evaluation in patients with hypertension
- Real‑world applicability
The trial tests whether adding vicadrostat to standard therapy improves results. Standard therapy includes empagliflozin. The primary goal is to lower cardiovascular death, heart‑failure hospitalisation, and urgent heart‑failure visits.
Nutritional and Metabolic Diseases
The Eisenach centre is evaluating novel insulin regimens. The focus is on improving glycaemic control. One trial enrols patients with type 1 diabetes. Another trial enrols patients with type 2 diabetes.
- Once‑weekly insulin icodec versus daily basal insulin
- Combination with insulin aspart in type 1 diabetes
- Intensification strategy for type 2 diabetes on oral therapy
- Safety and efficacy in routine practice
Researchers compare a once‑weekly insulin analogue, icodec, with daily basal insulins. The aim is to simplify dosing while maintaining safety and effectiveness.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novo Nordisk A/S1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis für Diabetologie, Angiologie und Innere Medizin Eisenach
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pragmatic Study Evaluating the Efficacy of Once-Weekly Insulin Icodec Versus Daily Basal Insulin Analogues in Insulin-Naïve Adults with Type 2 Diabetes | Novo Nordisk A/S | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Insulin Glargine | 3 | Unknown | 2023-08-02 | 2025-08-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.